Testing the sensitivity and specificity of EUROLINE immunoblots for systemic sclerosis and autoimmune muscle diseases

• Conditions: M34.0; M34.1; M34.8; M34.9; L94.0; M33.0; M33.1; M33.2; M33.9; M60.9

• Registration Number: DRKS00030945
• Lead Sponsor: niversitätsklinikum Halle Saale, Klinik für Innere Medizin II, Rheumatologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-01
• Study Completion: 2023-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1373

Inclusion Criteria

Outpatient and inpatient treatment at UKH in the period from 01.01.2018 to 31.12.2021.
- Existing test result in the immunoblot EUROLINE for a systemic sclerosis or autoimmune muscle disease.
- Confirmed diagnosis by the clinical phenotype of one of the above-mentioned forms of progression, documented in the medical report or in the medical outpatient documentation.

Exclusion Criteria

- Positive blot results without documented diagnosis in the physician's report or in the physician's outpatient documentation

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sensitivity and specificity of the immunoblot EUROLINE

Secondary Outcome Measures

Name	Time	Method
ikelihood Ratio for the Immunoblot EUROLINE